GlaxoSmithKline has increased its share in biopharmaceutical company Theravance, the firm’s development partner of Relovair, a once-daily treatment for asthma and chronic obstructive pulmonary disease (COPD).
Following approval by Theravance stockholders on 15 May 2012, GSK now owns 25.8 million shares, or 26.7% of Theravance common stock.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GSK initially purchased 10 million shares for $21.29 apiece.
Theravance entered into a long-term agreement with GSK in November 2002 for the development of inhaled corticosteroid (ICS) / LABA combination, Relovair.
The drug, which has now completed its Phase 3 development, is a follow-up of GSK’s blockbuster Advair which expired in September 2010.
GSK intends to submit regulatory applications for Relovair for the treatment of COPD in the US and Europe, in mid-2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFor asthma, the firm also plans to submit an application in Europe in mid-2012 and GSK and Theravance are reviewing the strategy for a future US filing.
